Share this article
Share this article
RADNOR, Pa. and GENEVA, Switzerland, Dec. 30, 2020 /PRNewswire/ NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) ( Relief ) today announced the conclusion of enrollment in the phase 2b/3 trial of ZYESAMI™ (previously RLF-100
TM: aviptadil) for the treatment of Respiratory Failure in patients with Critical COVID-19 (www.clinicaltrials.gov NCT04311697). No drug-related serious adverse events have been reported as of today. Enrollment was increased from 165 patients in order to amass as large a safety database as possible. Top line data are expected in late January - early February 2021. With FDA s authorization and the extraordinary dedication of our twelve clinical trial sites, we were able to take a drug not formulated or administered to patients in IV form since 2005 and advance it to the clinic in ten weeks. We hope that the highly encouraging results seen in the most critically-ill COVID-19 patients treat
EQS-News: Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100 for Critical COVID-19 with Respiratory Failure
direktbroker.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from direktbroker.de Daily Mail and Mail on Sunday newspapers.
NeuroRx and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure
wfmz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wfmz.com Daily Mail and Mail on Sunday newspapers.